Q-omics provides the consensus-scored SDHAF3 profile across patient tissues and cancer cell-line models. SDHAF3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, SDHAF3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SDHAF3 RNA expression shows 18,022 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, KIRC, and ACC as cancer lineages where SDHAF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SDHAF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SDHAF3 survival associations across molecular data types. SDHAF3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SDHAF3 RNA expression–survival associations across cancer types. High SDHAF3 expression shows unfavorable associations in LGG and SCLC, but favorable associations in OV, MESO, LUSC and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for SDHAF3 RNA expression.
This table summarizes SDHAF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SDHAF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SDHAF3 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in HNSC, LUAD and UCEC. The KIRC box plot shows higher SDHAF3 RNA expression in normal versus tumor tissue (log2 FC = −0.663, t-test p < 0.001).
This table shows molecular features associated with SDHAF3 in patient tissues and cancer cell lines. In patient samples, SDHAF3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SDHAF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
